๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer

โœ Scribed by Nelson, Robert L.


Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
603 KB
Volume
10
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

The pharmacokinetics of vindesine, vincristine, and vinblastine were investigated in patients with cancer. All drugs were administered rapidly via intravenous injection, and drug levels were determined in serum obtained at intervals after injection by radioimmunoassay. All three drugs exhibited a triphasic serum decay pattern, with no major differences in alpha or beta phase halfโ€lives noted among them. However, vincristine had a longer and more variable terminal phase halfโ€life (85 ยฑ 69 hr) than vindesine (24 ยฑ 10 hr) or vinblastine (25 ยฑ 7 hr). Central compartment volumes were also different. The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/ kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr). These differences correlate well with the results of similar studies done in animals, with acute LD~50~ data in mice, and with the usually employed weekly clinical doses for these drugs. These findings support the hypothesis that differences in the toxicities of these alkaloids may be related in part to differences in their pharmacokinetics.


๐Ÿ“œ SIMILAR VOLUMES


Combined actinomycin D and vincristine i
โœ Raul E. Chanes; Paul T. Condit; Richard H. Bottomley; William Nisimblat ๐Ÿ“‚ Article ๐Ÿ“… 1971 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 313 KB ๐Ÿ‘ 2 views

A combination of actinomycin D and vincristine has been used to treat 92 patients with various kinds of cancer. The best results were obtained in patients with lung cancer, with a n initial response rate of 6096 and an average duration of remission of over 8 months. Some patients with sarcomas and m

Increasing the dosage of vincristine : A
โœ Stewart J. Kellie; Pauline Koopmans; John Earl; Christa Nath; Derek Roebuck; Don ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 93 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Vincristine (VCR) is widely used to treat patients with malignant disease; among the patients treated with VCR are children with brain tumors. In vitro studies have demonstrated that the cytotoxic activity of VCR is related to both extracellular concentration and duration

Pharmacokinetic, biochemical and clinica
โœ Mark Clemons; Malcolm Ranson; Jennifer M. Margison; Hassan El Teraifi; Audrey Gr ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 107 KB

## Abstract We assessed whether split dosing with the methylating agent DTIC is an effective strategy for inactivating the DNA repair protein __O__6โ€alkylguanine DNAโ€ATase in order to decrease tumour resistance to BCNU. ATase levels in PBMCs were used as a surrogate for tumour ATase depletion to de